{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T18:44:44Z","timestamp":1788893084962,"version":"build-2803163510"},"reference-count":45,"publisher":"The Endocrine Society","issue":"10","license":[{"start":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T00:00:00Z","timestamp":1786752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000738","name":"Veterans Affairs","doi-asserted-by":"publisher","award":["001"],"award-info":[{"award-number":["001"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020940","name":"NIH","doi-asserted-by":"publisher","award":["K08CA222620"],"award-info":[{"award-number":["K08CA222620"]}],"id":[{"id":"10.13039\/100020940","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009141","name":"Cancer League of Colorado","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013678","name":"University of Colorado Cancer Center","doi-asserted-by":"publisher","award":["P30-CA046934"],"award-info":[{"award-number":["P30-CA046934"]}],"id":[{"id":"10.13039\/100013678","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Adrenocortical carcinoma (ACC) is an aggressive malignancy with no approved targeted therapy and poor outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using multiple patient-derived xenograft (PDX) and cell line xenograft (CLX) models, and a newly developed PDX model (CUACC9), we investigated the potential action of the multikinase inhibitor OTSSP167 for treatment of ACC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>OTSSP167 effectively reduced tumor growth in wild-type TP53 (CUACC1) and mutant TP53 (H295R, CUACC9) in vivo tumor models. Immunohistochemical analysis of treated tumors verified apoptosis via caspase activation as a mechanism of OTSSP167 action. Further evaluation of downstream effectors via RNAseq and a reverse phase protein array (RPPA), using ACC cell lines matching the in vivo genetic diversity, demonstrated that OTSSP167 impeded cell cycle via G2\/M arrest independent of TP53 status. In TP53 mutant lines, OTSSP167 enhanced DNA damage and inhibited protein synthesis. RSK1 was identified as a direct target of OTSSP167 activity in vitro. OTSSP167 also induced the G2\/M checkpoint protein, WEE1, activation in all models, indicating an early adaptive response. Combining the WEE1 inhibitor AZD1775 with OTSSP167 significantly enhanced cytotoxicity in TP53 mutant lines, and reduced tumor growth in a TP53 mutant ACC model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Together these findings establish the feasibility of using OTSSP167 in ACC, especially in TP53 mutant ACC tumors. In addition, this study demonstrates the possibility of targeting the early adaptive response subsequent to exposure to OTSSP167 treatment. Our findings provide strong rationale for a future phase I clinical trial in ACC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/endocr\/bqag091","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T11:32:45Z","timestamp":1786707165000},"source":"Crossref","is-referenced-by-count":1,"title":["Comprehensive profiling of OTSSP167 action in adrenocortical carcinoma"],"prefix":"10.1210","volume":"167","author":[{"given":"Adwitiya","family":"Kar","sequence":"first","affiliation":[{"name":"Divisions of Endocrinology, Metabolism and Diabetes, University of Colorado , Aurora, CO 80045 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapahsama","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Divisions of Endocrinology, Metabolism and Diabetes, University of Colorado , Aurora, CO 80045 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8574-1972","authenticated-orcid":false,"given":"Nikita","family":"Pozdeyev","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, University of Colorado School of Medicine , Aurora, CO 80045 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa B","family":"Holmstoen","sequence":"additional","affiliation":[{"name":"Divisions of Endocrinology, Metabolism and Diabetes, University of Colorado , Aurora, CO 80045 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey J","family":"Foust","sequence":"additional","affiliation":[{"name":"Divisions of Endocrinology, Metabolism and Diabetes, University of Colorado , Aurora, CO 80045 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey M","family":"Bagby","sequence":"additional","affiliation":[{"name":"Medical Oncology, Department of Medicine, University of Colorado , Aurora, CO 80045 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd M","family":"Pitts","sequence":"additional","affiliation":[{"name":"Medical Oncology, Department of Medicine, University of Colorado , Aurora, CO 80045 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouhammed Amir","family":"Habra","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center , Houston, TX 77030 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7634-1093","authenticated-orcid":false,"given":"Margaret E","family":"Wierman","sequence":"additional","affiliation":[{"name":"Divisions of Endocrinology, Metabolism and Diabetes, University of Colorado , Aurora, CO 80045 ,","place":["USA"]},{"name":"Research Service Rocky Mountain Regional Veterans Affairs Medical Center , Aurora, CO 80045 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3341-582X","authenticated-orcid":false,"given":"Katja","family":"Kiseljak-Vassiliades","sequence":"additional","affiliation":[{"name":"Divisions of Endocrinology, Metabolism and Diabetes, University of Colorado , Aurora, CO 80045 ,","place":["USA"]},{"name":"Research Service Rocky Mountain Regional Veterans Affairs Medical Center , Aurora, CO 80045 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,8,15]]},"reference":[{"issue":"10","key":"2026090804165064700_bqag091-B1","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1210\/clinem\/dgad199","article-title":"New findings on presentation and outcome of patients with adrenocortical cancer: results from a National Cohort Study","volume":"108","author":"Puglisi","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026090804165064700_bqag091-B2","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1210\/er.2013-1029","article-title":"Adrenocortical carcinoma","volume":"35","author":"Else","year":"2014","journal-title":"Endocr Rev"},{"issue":"4","key":"2026090804165064700_bqag091-B3","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12040941","article-title":"Efficacy of the EDP-M scheme plus adjunctive surgery in the management of patients with advanced adrenocortical carcinoma: the Brescia experience","volume":"12","author":"Lagan\u00e0","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2026090804165064700_bqag091-B4","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1210\/jc.2017-02591","article-title":"Mitotane monotherapy in patients with advanced adrenocortical carcinoma","volume":"103","author":"Megerle","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2026090804165064700_bqag091-B5","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S2213-8587(23)00193-6","article-title":"Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study","volume":"11","author":"Terzolo","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"2026090804165064700_bqag091-B6","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/MED.0000000000000543","article-title":"Update on in-vivo preclinical research models in adrenocortical carcinoma","volume":"27","author":"Kar","year":"2020","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"11","key":"2026090804165064700_bqag091-B7","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1210\/js.2018-00197","article-title":"Therapeutic targets for adrenocortical carcinoma in the genomics era","volume":"2","author":"Mohan","year":"2018","journal-title":"J Endocr Soc"},{"issue":"5","key":"2026090804165064700_bqag091-B8","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccell.2016.04.002","article-title":"Comprehensive pan-genomic characterization of adrenocortical carcinoma","volume":"29","author":"Zheng","year":"2016","journal-title":"Cancer Cell"},{"issue":"6","key":"2026090804165064700_bqag091-B9","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/ng.2953","article-title":"Integrated genomic characterization of adrenocortical carcinoma","volume":"46","author":"Assi\u00e9","year":"2014","journal-title":"Nat Genet"},{"issue":"7","key":"2026090804165064700_bqag091-B10","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1210\/en.2018-00310","article-title":"Elucidating the role of the maternal embryonic leucine zipper kinase in adrenocortical carcinoma","volume":"159","author":"Kiseljak-Vassiliades","year":"2018","journal-title":"Endocrinology"},{"issue":"3","key":"2026090804165064700_bqag091-B11","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1158\/2767-9764.CRC-24-0085","article-title":"Activity of the ubiquitin-activating enzyme inhibitor TAK-243 in adrenocortical carcinoma cell lines, patient-derived organoids, and murine xenografts","volume":"4","author":"Arakawa","year":"2024","journal-title":"Cancer Res Commun"},{"issue":"3","key":"2026090804165064700_bqag091-B12","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1182\/bloodadvances.2022008548","article-title":"Antileukemic properties of the kinase inhibitor OTSSP167 in T-cell acute lymphoblastic leukemia","volume":"7","author":"Bridges","year":"2023","journal-title":"Blood Adv"},{"issue":"4","key":"2026090804165064700_bqag091-B13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153518","article-title":"OTSSP167 abrogates mitotic checkpoint through inhibiting multiple mitotic kinases","volume":"11","author":"Ji","year":"2016","journal-title":"PLoS One"},{"issue":"12","key":"2026090804165064700_bqag091-B14","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-019-0249-x","article-title":"Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma","volume":"9","author":"Maes","year":"2019","journal-title":"Blood Cancer J"},{"issue":"2","key":"2026090804165064700_bqag091-B15","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.stemcr.2014.12.006","article-title":"EZH2 protects glioma stem cells from radiation-induced cell death in a MELK\/FOXM1-dependent manner","volume":"4","author":"Kim","year":"2015","journal-title":"Stem Cell Rep"},{"issue":"10","key":"2026090804165064700_bqag091-B16","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1016\/j.celrep.2017.11.033","article-title":"MELK promotes melanoma growth by stimulating the NF-\u03baB pathway","volume":"21","author":"Janostiak","year":"2017","journal-title":"Cell Rep"},{"issue":"1","key":"2026090804165064700_bqag091-B17","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-022-02464-5","article-title":"Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer","volume":"41","author":"Laha","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"issue":"24","key":"2026090804165064700_bqag091-B18","doi-asserted-by":"crossref","first-page":"8195","DOI":"10.1074\/jbc.REV120.013433","article-title":"The controversy surrounding its complex role in cancer","volume":"295","author":"McDonald","year":"2020","journal-title":"J Biol Chem"},{"key":"2026090804165064700_bqag091-B19","article-title":"Development and maintenance of a preclinical patient derived tumor xenograft model for the investigation of novel anti-cancer therapies","volume":"118","author":"Bagby","year":"2016","journal-title":"J Vis Exp"},{"issue":"4","key":"2026090804165064700_bqag091-B20","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1530\/ERC-17-0447","article-title":"Development of new preclinical models to advance adrenocortical carcinoma research","volume":"25","author":"Kiseljak-Vassiliades","year":"2018","journal-title":"Endocr Relat Cancer"},{"issue":"Suppl 4","key":"2026090804165064700_bqag091-B21","first-page":"65","article-title":"Growth rate analysis and efficient experimental design for tumor xenograft studies","volume":"13","author":"Hather","year":"2014","journal-title":"Cancer Inform"},{"key":"2026090804165064700_bqag091-B22","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12123857","article-title":"Proteomic resistance biomarkers for PI3K inhibitor in triple negative breast cancer patient-derived xenograft models","volume":"12","author":"Guo","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026090804165064700_bqag091-B23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.607282","article-title":"Testing cancer immunotherapy in a human immune system mouse model: correlating treatment responses to human chimerism, therapeutic variables and immune cell phenotypes","volume":"12","author":"Marin-Jimenez","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"2026090804165064700_bqag091-B24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-Seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"issue":"2","key":"2026090804165064700_bqag091-B25","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","article-title":"HTSeq\u2014a Python framework to work with high-throughput sequencing data","volume":"31","author":"Anders","year":"2015","journal-title":"Bioinformatics"},{"issue":"12","key":"2026090804165064700_bqag091-B26","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"issue":"1","key":"2026090804165064700_bqag091-B27","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-76603-3","article-title":"VolcaNoseR is a web app for creating, exploring, labeling and sharing volcano plots","volume":"10","author":"Goedhart","year":"2020","journal-title":"Sci Rep"},{"issue":"16","key":"2026090804165064700_bqag091-B28","doi-asserted-by":"crossref","DOI":"10.21769\/BioProtoc.2517","article-title":"Rapid profiling cell cycle by flow cytometry using concurrent staining of DNA and mitotic markers","volume":"7","author":"Shen","year":"2017","journal-title":"Bio Protoc"},{"issue":"1","key":"2026090804165064700_bqag091-B29","doi-asserted-by":"crossref","DOI":"10.1002\/cpmb.127","article-title":"Measuring protein synthesis in cultured cells and mouse tissues using the non-radioactive SUnSET assay","volume":"133","author":"Ravi","year":"2020","journal-title":"Curr Protoc Mol Biol"},{"key":"2026090804165064700_bqag091-B30","doi-asserted-by":"crossref","unstructured":"Kar A, Banerjee T, Pozdeyev N, et al \u00a0Comprehensive profiling of OTSSP167 action in adrenocortical carcinoma models digital repository. 2026. Doi: 10.5281\/zenodo.21628157","DOI":"10.1210\/endocr\/bqag091"},{"issue":"35","key":"2026090804165064700_bqag091-B31","doi-asserted-by":"crossref","first-page":"9810","DOI":"10.1073\/pnas.1606862113","article-title":"Mitotic MELK-eIF4B signaling controls protein synthesis and tumor cell survival","volume":"113","author":"Wang","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026090804165064700_bqag091-B32","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201708274","article-title":"Identification of potential therapeutic targets in prostate cancer through a cross-species approach","volume":"10","author":"Jurmeister","year":"2018","journal-title":"EMBO Mol Med"},{"issue":"3","key":"2026090804165064700_bqag091-B33","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-021-00433-3","article-title":"OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia","volume":"11","author":"Eisfelder","year":"2021","journal-title":"Blood Cancer J"},{"issue":"2","key":"2026090804165064700_bqag091-B34","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1042\/BJ20110289","article-title":"Regulation and function of the RSK family of protein kinases","volume":"441","author":"Romeo","year":"2012","journal-title":"Biochem J"},{"issue":"12","key":"2026090804165064700_bqag091-B35","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1038\/sj.emboj.7601166","article-title":"The mTOR\/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity","volume":"25","author":"Shahbazian","year":"2006","journal-title":"Embo J"},{"issue":"9","key":"2026090804165064700_bqag091-B36","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-021-01098-8","article-title":"WEE1 inhibitor: clinical development","volume":"23","author":"Kong","year":"2021","journal-title":"Curr Oncol Rep"},{"issue":"33","key":"2026090804165064700_bqag091-B37","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1200\/JCO.21.01435","article-title":"Inhibition of WEE1 is effective in TP53- and RAS-mutant metastatic colorectal cancer: a randomized trial (FOCUS4-C) comparing adavosertib (AZD1775) with active monitoring","volume":"39","author":"Seligmann","year":"2021","journal-title":"J Clin Oncol"},{"issue":"40","key":"2026090804165064700_bqag091-B38","doi-asserted-by":"crossref","first-page":"67526","DOI":"10.18632\/oncotarget.18728","article-title":"Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer","volume":"8","author":"Ku","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"2026090804165064700_bqag091-B39","article-title":"MELK is an oncogenic kinase essential for metastasis, mitotic progression, and programmed death in lung carcinoma","volume":"5","author":"Tang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"2026090804165064700_bqag091-B40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0172832","article-title":"Genome-wide effects of MELK-inhibitor in triple-negative breast cancer cells indicate context-dependent response with p53 as a key determinant","volume":"12","author":"Simon","year":"2017","journal-title":"PLoS One"},{"issue":"10","key":"2026090804165064700_bqag091-B41","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.tips.2016.06.006","article-title":"Targeting WEE1 kinase in cancer","volume":"37","author":"Matheson","year":"2016","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"2026090804165064700_bqag091-B42","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-020-00959-2","article-title":"A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target","volume":"13","author":"Ghelli Luserna di Ror\u00e0","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"16","key":"2026090804165064700_bqag091-B43","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1158\/1078-0432.CCR-14-0720","article-title":"CHK it out! Blocking WEE kinase routs TP53 mutant cancer","volume":"20","author":"Bauman","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2026090804165064700_bqag091-B44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057523","article-title":"Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas","volume":"8","author":"Kreahling","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"2026090804165064700_bqag091-B45","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1530\/ERC-21-0040","article-title":"Targeted genomic analysis of 364 adrenocortical carcinomas","volume":"28","author":"Pozdeyev","year":"2021","journal-title":"Endocr Relat Cancer"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/endo\/advance-article-pdf\/doi\/10.1210\/endocr\/bqag091\/70653144\/bqag091.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/endo\/article-pdf\/167\/10\/bqag091\/70653144\/bqag091.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/endo\/article-pdf\/167\/10\/bqag091\/70653144\/bqag091.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T08:17:06Z","timestamp":1788855426000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/doi\/10.1210\/endocr\/bqag091\/8761843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,15]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9,3]]}},"URL":"https:\/\/doi.org\/10.1210\/endocr\/bqag091","relation":{},"ISSN":["1945-7170"],"issn-type":[{"value":"1945-7170","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,8,15]]},"article-number":"bqag091"}}